Hirudo troctina Hirudins
11 hirudin / HLF paralogs from the North-African medicinal leech — Ahmed 2024 documents highest hirudin gene diversity within the genus Hirudo and three recombination-derived chimeras.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- 11 hirudin / HLF paralogs from the North-African medicinal leech — Ahmed 2024 documents highest hirudin gene diversity within the genus Hirudo and three recombination-derived chimeras.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
H. troctina hirudins' in vitro thrombin inhibition does NOT establish clinical efficacy. No FDA-approved derivative exists; H. troctina is not the FDA-cleared K040187 medicinal leech species (H. medicinalis / H. verbana).
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 7,000 Da
- Source species
- Hirudo troctina
- Discovered
- 2024 · Ahmed RB et al.
Biological Targets
- → thrombin (Factor IIa) — variable potency by isoform
Key Citations
- Ahmed RB et al. (2024), Parasitol Res · PMID 39540973
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.